Dr. John L. Ryan Ph.D., M.D. serves as Executive Vice President, Chief Medical Officer of the Company. Prior to joining Kadmon, Dr. Ryan served as Senior Vice President and Chief Medical Officer of Cerulean Pharma, Inc., a publicly traded pharmaceutical company, from 2009 to 2011. Prior to joining Cerulean, Dr. Ryan was Chief Medical Officer at Aveo Pharmaceuticals, Inc., a publicly traded company, from 2006 to 2009. Prior to joining Aveo, Dr. Ryan served as Senior Vice President of Translational Research at Wyeth, a publicly traded specialty-pharmaceutical company (formerly Genetics Institute), where he served as head of the Department of Experimental Medicine, from 1995 to 2006. Dr. Ryan also served as an Executive Director of Clinical Research at Merck Research Laboratories from 1989 to 1995 and he previously served on the scientific advisory boards of ArQule, Inc. and Expression Analysis, Inc. Dr. Ryan received his B.S. and his Ph.D. from Yale University. Dr. Ryan received his M.D. from the University of California, San Diego.
John Ryan is 76, he's been the Executive Vice President、 Chief Medical Officer of Kadmon Inc since 2011. There are 1 older and 9 younger executives at Kadmon Inc. The oldest executive at Kadmon Holdings Inc is Eugene Bauer, 77, who is the Independent Director.
John's mailing address filed with the SEC is C/O KADMON HOLDINGS, INC., 450 E. 29TH STREET, NEW YORK, NY, 10016.
Over the last 8 years, insiders at Kadmon Inc have traded over 7,020,661$ worth of Kadmon Inc stock and bought 7,084,916 units worth 54,943,934$ . The most active insiders traders include Advisors Llcperceptive Life...、Asset Management Lp Golden ...、Daniel S Third Point Llc Loeb. On average, Kadmon Inc executives and independent directors trade stock every 29 days with the average trade being worth of 1,948,175$. The most recent stock trade was executed by Harlan Waksal on 13 March 2020, trading 16,000 units of KDMN stock currently worth 46,880$.
Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Its clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.
Kadmon Inc executives and other stock owners filed with the SEC include: